Abstract
Gliomatosis peritonei (GP) is a rare disease, usually associated with immature ovarian teratoma. GP may be rarely associated with mature ovarian teratoma. GP is composed of mature glial tissue elements, which histopathological examination can further confirm. Benign glial implants usually involve the omentum, peritoneum and lymph nodes. Many benign and malignant peritoneal diseases may mimic GP on clinical examination. GP may be confused with peritoneal carcinomatosis on computed tomography (CT) scan. A microscopic examination from peritoneal mass biopsy helps to rule out differential diagnosis. GP consists of mature glial tissue and is regarded as grade 0 according to the WHO grading of immature teratoma (IT). GP corresponds to a good prognosis with occasional cases showing malignant evolution.
Keywords: growing teratoma syndrome, teratoma, punctate fatty component, immature neuroepithelium, peritoneal glial implant
Introduction and background
Gliomatosis peritonei (GP) is identified by multiple nodules affecting the omentum and peritoneum, and it shows mature glial tissue on histological examination. GP may be associated with immature or mature ovarian teratoma [1-3]. Cases have been published regarding the association of GP with hepatic teratoma, gastric teratoma and even immature endometrial teratoma [4-6]. Two theories prevail regarding the aetiology of GP. According to the first theory, GP results from rupture of ovarian teratoma capsule or angio-lymphatic tumour spread [7]. However, the second concept suggests that foci of peritoneal glial tissue arise autonomously from Mullerian stem cells under favourable peritoneal conditions [8]. CT imaging is helpful for the diagnosis and follow-up of immature teratoma (IT) and peritoneal glial implants. Surgery is performed in GP associated with teratoma, whereas chemotherapy is recommended in the case of IT [9].
Review
Clinical and radiological features
IT clinically presents as a large pelvic mass, primarily turning up in the first three decades. Serum tumour markers like alpha-fetoprotein (AFP) are within normal limits [10]. On CT, IT shows some characteristic features. Mature teratoma (MT) are predominantly cystic tumours containing solid areas with large foci of fatty tissue that can be identified in radiology.
MT is usually well encapsulated with regular margins and foci of bony tissue within cystic elements. Compared to MT, IT is larger (14-25 cm) and shows predominantly solid components. IT usually presents with capsule perforation and irregular margins on a CT scan. Foci of punctate fatty tissue and scattered calcifications in a solid ovarian mass on CT scan discriminate IT from MT (Figure 1).
Figure 1. CT scan of immature teratoma ovary (Source: own photo).
Axial computed tomography image shows a mass lesion in the pelvis with scattered fat (black arrow) and calcific foci (white arrow)
The combination of positron emission tomography (PET) and CT gives the additional benefit of providing morphologic and functional details in the case of IT [11].
GP on CT scan can present as multiple nodules involving the peritoneum and omentum with free fluid in the peritoneal cavity. The size of the peritoneal nodule varies from 0.3 to 1.2 cm in diameter [12]. It is challenging to differentiate peritoneal metastasis from GP on radio-imaging alone. Glial nodules are usually small in size without any adipose tissue component, making it impossible to separate tuberculous peritonitis or peritoneal carcinomatosis from glial nodules on imaging (Figures 2A-2B).
Figure 2. CT scan images of gliomatosis peritonei (Source: own photo).
Post-contrast computed tomography (CT) axial section shows omental and mesenteric deposits in form of A) subtle fat stranding (arrow) and B) nodule (arrow)
Radiology provides details concerning tumour staging and further surgery planning [13].
Gross and morphology
Intraoperatively GP may mimic peritoneal carcinomatosis. Grossly, GP presents multiple nodules having size ranging from 1 to 10 mm in diameter. They are small, greyish and well-circumscribed involving parietal and visceral peritoneum and omentum. Grossly it is challenging to differentiate GP from tuberculosis. IT presents as a large ovarian mass having an irregular outer surface. Tumour is mostly unilateral with cut surface showing mainly solid areas with focal cystic regions along with necrosis and haemorrhage [9,10].
Microscopically, IT is defined by immature tissue components, mainly immature neuroepithelium in the form of rosettes and primitive neuroectodermal tissue in the background of mature teratomatous elements. Histology shows mitotically active primitive cells with dark hyperchromatic nuclei and glial tissue foci in the backdrop (Figures 3A-3D).
Figure 3. Immature teratoma ovary (Source: own photo).
A) Section shows primitive neuroepithelium (arrow) embedded in the fibrillary background (H&E; 4×). B) Immature component in the form of primitive neural tubules (star) (H&E; 20×). C) Section shows foci of the immature neuroepithelium (arrow) in the background of mature glial tissue (H&E; 20×). D) Low-power view showing mature components in the form of mature brain tissue (star) and mature bony tissue (arrow) (H&E; 10×).
IT may present with immature mesodermal tissue in the form of immature cartilage. Very rarely, IT may show immature endodermal tissue. The case of IT should not show components of a yolk sac tumour; otherwise, the case will be labelled as a mixed germ cell tumour. If a histological picture of IT and serum AFP levels are raised, further additional sampling must be carried out to rule out any component of the yolk sac tumour [9,10].
According to WHO classification of Female Genital Tumours, 5th Edition; grading is decided by examining immature neuroepithelium under a low-power microscopic view (40×). If the aggregated amount of neuroepithelium is present in one or less than one 40× field, it is grade 1; if present in one to three 40× fields, it is grade 2 and if present in more than three 40× fields, it is classified as grade 3 IT. Here, 40× power is equivalent to a 4.5 mm diameter view. Interestingly, pure GP is regarded as a grade 0 (zero) mature component. It shows multiple nodules of mature glial tissue beneath the surface [10] (Figures 4A-4D).
Figure 4. Gliomatosis peritonei histopathology (Source: own photo).
A) Ovarian surface multiple superficial nodules of mature glial tissue (star) (H&E; 10×). B) Metaplastic glial elements (star) with diffuse arrangement on ovarian surface in a case of immature teratoma grade 1. Underlying ovarian stroma is evident (arrow) (H&E; 10×). C) Omentum shows multiple glial nodules (star) with reactive inflammatory stroma (H&E; 10×). D) Peritoneum showing gliomatosis in the form of multiple tiny glial nodules (star) infiltrating fibrolipomatous stroma (H&E; 4×).
On immunohistochemistry, GP cells show characteristic positivity with SOX2 because SOX2 is necessary for preserving stem cell pluripotency and induction of neural cells origin from stem cells [14].
Genetic profile
Best et al. presented molecular studies in patients of ovarian mass diagnosed as IT with GP. Results showed that genetic changes in both lesions were mutually exclusive, indicating that neoplasms of IT and GP are genetically discrete. So, both are independent tumours, and GP does not represent tumour metastasis or tumour recurrence from IT mass [15]. Another study by Ferguson et al. showed heterozygosity at different microsatellite loci and homozygosity at the identical microsatellite loci of cases of the peritoneal glial nodule and ovarian IT mass, respectively. So, this leads to an impression that GP arises from pluripotent stem cells of Mullerian origin and is not related to primary ovarian teratoma [1].
Differential diagnosis
Growing teratoma syndrome (GTS) is a distinct entity characterised by a growing mass of MT in a known case of malignant germ cell tumour undergoing or having completed chemotherapy. GTS may contain mature tissue from any of three lineages, whilst GP shows only mature glial tissue. Unlike GTS, GP is not associated with chemotherapy treatment of malignant germ cell tumours [16].
In some cases of ovarian teratoma, predominantly MT components are seen. If clinically, radiologically and grossly suspicious of immature or malignant nature, then extensive sampling should be conducted to detect any immature neuroepithelium and also need for accurate grading of the immature component. Peritoneal carcinomatosis and tuberculous peritonitis can be easily differentiated from glial nodules on histology [9,10].
Prognosis and predictive factors
The patient is staged according to TNM staging of the ovary, fallopian tube and primary peritoneal carcinoma. Although GP is considered a stage III disease, its behaviour is mainly observed as benign [10].
GP is considered a grade 0 (zero), so it usually bears an overall favourable prognosis and is treated conservatively accordingly [13]. As GP lesion is mostly widespread, extensive surgical excision is indispensable. However, luckily, any residual lesion of GP is asymptomatic and requires no further action, which may vanish over a long period of time [17]. Treatment is not decided based on metastatic glial tissue component but on the grade of primary ovarian IT, as long as the glial tissue has been extensively sampled and contains only mature tissue [18]. Although, if the peritoneal glial component is immature, it is considered a metastatic teratoma and treated accordingly [13]. At present, due to the rarity of this lesion, data are scarce regarding how long these cases should be pursued for follow-up.
Conclusions
GP is an uncommon disease usually associated with IT of the ovary. In the case of ovarian teratoma, radio-imaging may help predict the immature or malignant nature of teratoma based on the identification of speckles of fatty tissue. In such suspected cases of IT, peritoneal and omental lesions should be searched, if any and should be excised along with ovarian mass to be sent for histopathological examination.
Grossly, throughout sampling should be carried out from ovarian mass to detect any immature neuroepithelium or other immature mesodermal components. A combined clinical, radiological and histopathological diagnostic approach is required to confirm the GP associated with IT and to differentiate it from its mimickers. It is also vital to acknowledge the benign mature nature of GP in most cases which helps to avert any avoidable surgical procedure in young patients.
The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.
Footnotes
The authors have declared that no competing interests exist.
References
- 1.Glial implants in gliomatosis peritonei arise from normal tissue, not from the associated teratoma. Ferguson AW, Katabuchi H, Ronnett BM, Cho KR. Am J Pathol. 2001;159:51–55. doi: 10.1016/S0002-9440(10)61672-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Gliomatosis peritonei combined with mature ovarian teratoma: immunohistochemical observations. Gocht A, Lohler J, Scheidel P, Stegner HE, Saeger W. Path Res Pract . 1995;191:1029–1035. doi: 10.1016/S0344-0338(11)80603-5. [DOI] [PubMed] [Google Scholar]
- 3.Immature ovarian teratoma with mature peritoneal metastatic deposits showing glial, epithelial, and endometrioid differentiation: a case report and review of the literature. Calder CJ, Light AM, Rollason TP. Int J Gynecol Pathol. 1994;13:279–282. doi: 10.1097/00004347-199407000-00013. [DOI] [PubMed] [Google Scholar]
- 4.Hepatic teratoma and peritoneal gliomatosis: a case report. Karlo C, Leschka S, Dettmer M, Breitenstein S, Stolzmann P. Cases J. 2009;2:9302. doi: 10.1186/1757-1626-2-9302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Peritoneal gliomatosis from a gastric teratoma. Coulson WF. Am J Clin Pathol. 1990;94:87–89. doi: 10.1093/ajcp/94.1.87. [DOI] [PubMed] [Google Scholar]
- 6.Coexistent immature teratoma of the uterus and endometrial adenocarcinoma complicated by gliomatosis peritonei. Ansah-Boateng Y, Wells M, Poole DR. Gynecol Oncol . 1985;21:106–110. doi: 10.1016/0090-8258(85)90240-9. [DOI] [PubMed] [Google Scholar]
- 7.Ovarian teratoma with glial implants on the peritoneum: an analysis of 12 cases. Robboy SJ, Scully RE. Hum Pathol . 1970;1:643–653. doi: 10.1016/s0046-8177(70)80062-4. [DOI] [PubMed] [Google Scholar]
- 8.Critical commentary to “Gliomatosis peritonei combined with mature ovarian teratoma”. Dallenbach-Hellweg G. https://pubmed.ncbi.nlm.nih.gov/8838374/ Pathol Res Pract . 1995;191:1037. [PubMed] [Google Scholar]
- 9.Gliomatosis peritonei arising in setting of immature teratoma of ovary: a case report and review of literature. Marwah N, Batra A, Gupta S, Singhal SR, Sen R. J Obstet Gynaecol India. 2016;66:192–195. doi: 10.1007/s13224-015-0708-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Vang R, Zaloudek C. WHO classification of female genital tumours, 5th ed. Vol. 70. Lyon: WHO Classification of Tumours Editorial Board, International Agency for Research on Cancer (IARC); 2020. Immature teratoma of the ovary; pp. 121–122. [Google Scholar]
- 11.The application of 18F-FDG PET/CT in ovarian immature teratomas when pathological examination results contradict clinical observations: a case report. Wang M, Jiang S, Zhang Y, Jiang C, Xia F, Lyu W, Ma X. Medicine. 2017;96:0. doi: 10.1097/MD.0000000000009171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Huge ovarian mature cystic teratoma with gliomatosis peritonei and massive ascites in a postmenopausal woman. Lin CS, Huang C, Li PC, Hsu YH, Ding DC. Ci Ji Yi Xue Za Zhi. 2019;31:289–291. doi: 10.4103/tcmj.tcmj_176_18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Mature ovarian teratoma with gliomatosis peritonei: a rare case report. Bajracharya A, Shrestha S, Singh M, Dhakal HP. Clin Case Rep. 2021;9:0. doi: 10.1002/ccr3.4879. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Gliomatosis peritonei: a clinicopathologic and immunohistochemical study of 21 cases. Liang L, Zhang Y, Malpica A, Ramalingam P, Euscher ED, Fuller GN, Liu J. Mod Pathol. 2015;28:1613–1620. doi: 10.1038/modpathol.2015.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Molecular analysis of an immature ovarian teratoma with gliomatosis peritonei and recurrence suggests genetic independence of multiple tumours. Best DH, Butz GM, Moller K, Coleman WB, Thomas DB. Int J Oncol . 2004;25:17–25. [PubMed] [Google Scholar]
- 16.Growing teratoma syndrome and peritoneal gliomatosis. Mrabti H, El Ghissassi I, Sbitti Y, Amrani M, Hachi H, Errihani H. Case Rep Med. 2011;2011:123527. doi: 10.1155/2011/123527. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Gliomatosis peritonei: a particular entity with specific outcomes within the growing teratoma syndrome. Bentivegna E, Gonthier C, Uzan C, Genestie C, Duvillard P, Morice P, Gouy S. Int J Gynecol Cancer. 2015;25:244–249. doi: 10.1097/IGC.0000000000000345. [DOI] [PubMed] [Google Scholar]
- 18.Imaging features of unusual lesions and complications associated with ovarian mature cystic teratoma. Srisajjakul S, Prapaisilp P, Bangchokdee S. Clin Imaging. 2019;57:115–123. doi: 10.1016/j.clinimag.2019.05.013. [DOI] [PubMed] [Google Scholar]




